×
Dr. Yvonne Karamagi briefs the UNITAID-CHAI Community Advisory Board on the Mildmay Uganda growth path

Our impact through our beneficiaries’ eyes.

260,000
Estimated Disability adjusted life years averted every year
31,000
Estimated unplanned Pregnancies Avoided every year
7,000
Estimated New Infections averted every year
3,000
TB patients treated of TB every year
30,000
Sexually active men given voluntary male circumcision
12,000
HIV positive people tested and enrolled on ART
3
MTCT Percentage Rate in Areas supported over 3 years (Previously at 43%)

UNITAID-CHAI Community Advisory Board visits Mildmay Uganda Hospital

Created On : 17 May 2018 - Last Updated : 17 May 2018

A consortium from UNITAID-CHAI Community Advisory Board visited Mildmay Uganda Hospital to interface with patients and clinicians on Dolutegravir (DTG) as one of the partners piloting this new drug.

According Dr. Atim Joan, Hospital DTG roll out Focal Person at Mildmay Uganda Hospital, the exercise is on-going and expect to reach about 1200 clients.

Jovia (on DTG) tells her experience

“I make a living through transactional sex.  Unfortunately, the regimen I was on previously was not user friendly given my type of job. I normally go to meet my clients at night however the issue of sleep and weakness would distract my plans and this forced me to forgo my drugs sometimes. Fortunately, I was introduced to DTG and I find it very good, I take it in the morning and can continue with my planned schedules uninterrupted with sleep. It actually feels like I am not on any medication,” said Jovia one of the pioneer DTG clients.

In 2017, Ministry of Health (MoH) introduced Dolutegravir (DTG) as a new drug to replace Nevirapine (NVP) and Efavirenz (EFV). Dolutegravir (DTG) is used to suppress the viral load and is taken as one tablet of 50 mg once daily together with other antiretroviral drugs. Over 300 clients have been enrolled on DTG at Mildmay Uganda Hospital.


You might also like